Register for the upcoming W.E.S.T. Hour


Please fill out this form to register for the upcoming W.E.S.T. Hour Webinar: Strategies and Solutions for Succeeding in the Development of RNA-based Nanomedicines presented by Dr. Viet Anh Nguyen Huu, Senior Field Application Scientist with Precision NanoSystems.


Date: Wednesday, September 13, 2023

Time: 9:00am PT / 11:00am CT




Nucleic acids (e.g., siRNA, mRNA and saRNA) can be designed and formulated to silence, express, and edit specific genes providing a flexible and powerful approach to preventing and treating diseases. The recent commercialization and widespread distribution of COVID-19 mRNA vaccines has exemplified the massive potential to rapidly develop and scale-up new genomic medicines to protect from emerging viral threats and treat a wide range of serious diseases with unmet medical needs. 

As part of Danaher Life Sciences, Precision Nanosystems provides end-to-end, synergistic solutions and services to enable successful development of Genomic Medicines. Our BioPharma Services Team can de-risk and accelerate the development of promising RNA-LNP drug candidates for clinical evaluation and successful commercialization.

This webinar will discuss key insights and experiences that leverage modular microfluidic platform technologies and analytics to enable rapid development, testing, and scale-up of mRNA-LNP vaccines and therapeutics:


- An overview of Precision NanoSystem’s BioPharma Services to enable and support each step in the client’s development process. In this presentation we will provide examples from our internal R&D work to demonstrate the versatility of the genomic medicine toolbox for the rapid development of RNA-LNP Vaccines


- Key considerations during development of mRNA-LNP medicines and how a comprehensive understanding of Critical Quality Attributes (CQAs) and Key process parameters are critical in developing mRNA-LNP that meet the target product profile 


- How a “toolbox” comprised of a RNA drug substance platform, a lipid nanoparticle drug delivery platform, and a microfluidic manufacturing platform can provide rapid development and scale-up of genomic medicines